David H. Henry, M.D.

faculty photo
Clinical Professor of Medicine (Hematology-Oncology)
Department: Medicine

Contact information
Penn Hematology/Oncology
Abramson Cancer Center
Pennsylvania Hospital, Farm Journal Building
230 West Washington Square
Philadelphia, PA 19106
Office: 215-829-6088
Fax: 215-829-6104
Princeton University, 1970.
University of Pennsylvania School of Medicine, 1975.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Paul G Rubinstein, MD, Page C Moore, PhD, Milan Bimali, PhD, Jeanette Y Lee, PhD, Michelle A Rudek, PhD, Amy Chadburn, MD, Lee Ratner, MD, David H Henry, MD, Ethel Cesarman, MD, Camille E DeMarco, MPH, Dominique Costagliola, PhD, Yassine Taoufik, PhD, Juan Carlos Ramos, MD, Elad Sharon, MD, Erin G Reid, MD, Richard F Ambinder, MD, Ronald Mitsuyasu, MD, Nicolas Mounier, MD, Caroline Besson, MD, Ariela Noy, MD for the AIDS Malignancy Consortium and the Lymphoma Study Association † : Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. The Lancet 10(8): E624-E632, August 2023.

David Henry: A Commentary On: Neoadjuvant Chemoradiation for Treatment of LARC. Practice Update June 2023.

David Henry: A commentary on: Circulating Tumor DNA Following Neoadjuvant Chemotherapy and Surgery in ER-Positive and HER2-Negative Breast Cancer. Practice Update June 2023.

David Henry: A Commentary On: Adjuvant Osimertinib for Resected EFGR-Mutated Stage Ib-IIIA NSCLC. Practice Update June 2023.

David Henry: A commentary on: Nivolumab Plus Brentuximab Vedotin for Low-Risk Relapsed Classic Hodgkin Lymphoma. Practice Update June 2023.

John A. Glaspy, Nashat Y Gabrail, Patricia A. Locantore-Ford, Gopal C Saha, Elise Hardy, Tyson Lee, Katharina Modelska, David H. Henry: Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies. Journal of Clinical Oncology January 2023.

David Henry: 2022 Top Story in Oncology: Durvalumab Plus Gemcitabine and Cisplatin as First-Line Treatment for Advanced Biliary Tract Cancer. Practice update December 2022.

David Henry: A commentary on: ASCO 2022: Abstract Recommendations. Practice Update June 2022.

Henry, DH., Maki RG: Lenalidomide and the expanding toolkit to manage Kaposi sarcoma. Clin Canc Res 28(12): 2485-2487, Jun 13 2022.

Hajizadeh Barfejani, A; Prasad, S; Henry, D.: SAFE ADMINISTRATION OF SECOND DOSE OF MRNA COVID-19 VACCINE FOLLOWING DEVELOPMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA. HemaSphere 6: 2093-2194, June 2022 Notes: DOI: 10.1097/01.HS9.0000852120.42895.8a.

back to top
Last updated: 08/02/2023
The Trustees of the University of Pennsylvania